Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
34 Results for "
SNCA
" in MedChemExpress (MCE) Product Catalog:
Products (34)
34 Results for "SNCA" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-P70577
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuclein; Synuclein, Alpha (Non A4 Component Of Amyloid Precursor); Α-Synuclein; Synuclein Alpha; Non A4 Component Of Amyloid Precursor
Species:
Human
Source:
E. coli
2
2 Cited Publications
Synonyms: NSC 377363 hydrochloride
Target:
Research Areas:
Synucleozid hydrochloride (NSC 377363 hydrochloride) is a potent inhibitor of the?SNCA?mRNA?that encodes α-synuclein protein. Synucleozid selectively?targets the?α-synuclein?mRNA 5′ UTR at the designed IRE site, decreases the amount of?SNCA?mRNA loaded into polysomes and thereby inhibits?SNCA?translation. Synucleozid has the potential for the investigation of Parkinson’s disease .
1
1 Cited Publications
Cat. No.: HY-P71327
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
E. coli
1
Cat. No.: HY-P990898
CAS No.: 2850367-41-6
Synonyms: Lu-AF82422
Target:
Research Areas:
Cat. No.: HY-401209
CAS No.: 613226-91-8
Target:
Research Areas:
Synucleozid-2.0 is a blood-brain barrier-permeable inhibitor that binds to the IRE of SNCA mRNA, with a EC50 of 2.9 µM and a Kd value of 1.8 µM. Synucleozid-2.0 selectively binds to and stabilizes the A bulge and adjacent closed base pairs in the 5' UTR IRE of SNCA mRNA, blocks the translation process and reduces intracellular levels of α-synuclein. Synucleozid-2.0 exerts cytoprotective effects against cytotoxicity induced by α-synuclein preformed fibrils. Synucleozid-2.0 is applicable to the research of Parkinson's disease .
Cat. No.: HY-135902
CAS No.: 502139-01-7
Synonyms: NSC 377363
Target:
Research Areas:
Synucleozid (NSC 377363) is a potent inhibitor of the SNCA mRNA that encodes α-synuclein protein. Synucleozid selectively targets the α-synuclein mRNA 5′ UTR at the designed IRE site, decreases the amount of SNCA mRNA loaded into polysomes and thereby inhibits SNCA translation. Synucleozid has the potential for the investigation of Parkinson’s disease .
Cat. No.: HY-RS13482
Target:
Research Areas:
SNCA Human Pre-designed siRNA Set A contains three designed siRNAs for SNCA gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS13483
Target:
Research Areas:
Snca Mouse Pre-designed siRNA Set A contains three designed siRNAs for Snca gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-RS13484
Target:
Research Areas:
Snca Rat Pre-designed siRNA Set A contains three designed siRNAs for Snca gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
Cat. No.: HY-P990922
CAS No.: 2864437-88-5
Synonyms: MEDI-1341; TAK-341
Target:
Research Areas:
Cat. No.: HY-P705391
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Cynomolgus
Source:
E. coli
Cat. No.: HY-P70660
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Mouse
Source:
E. coli
Cat. No.: HY-P704891
Purity: ≥ 95%, as determined by Bis-Tris PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
E. coli
Cat. No.: HY-P704889
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
HEK293
Cat. No.: HY-P704892
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
E. coli
Cat. No.: HY-P704890
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
E. coli
Cat. No.: HY-P704895
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: SNCA; Parkinson Disease (Autosomal Dominant, Lewy Body) 4; Prev. PARK1; Non-A4 Component Of Amyloid Precursor; Prev. PARK4; Non A-Beta Component Of AD Amyloid; Alpha-Synuclein; Non-A Beta Component Of AD Amyloid; NACP; Synuclein Alpha-140; PD1; I+/--Synuc
Species:
Human
Source:
E. coli
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
